Denali Starts Dosing in Phase II Parkinsons Disease Study

DNLI Stock  USD 21.43  1.79  7.71%   
Under 55% of Denali Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding Denali Therapeutics suggests that many traders are impartial. Denali Therapeutics' investing sentiment shows overall attitude of investors towards Denali Therapeutics.
  
DNLI begins dosing in the phase IIa study on BIIB122 in approximately 50 participants with Parkinsons disease and LRRK2 pathogenic mutations confirmed by genetic testing.

Read at zacks.com
zacks News
  

Denali Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Denali Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Denali Therapeutics Fundamental Analysis

We analyze Denali Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Denali Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Denali Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Total Asset

Total Asset Comparative Analysis

Denali Therapeutics is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.

Denali Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Denali Therapeutics stock to make a market-neutral strategy. Peer analysis of Denali Therapeutics could also be used in its relative valuation, which is a method of valuing Denali Therapeutics by comparing valuation metrics with similar companies.

Peers

Denali Therapeutics Related Equities

RVMDRevolution Medicines   1.40   
0%
14.0%
BPMCBlueprint Medicines   1.14   
0%
11.0%
DAWNDay One   0.16   
0%
1.0%
GLUEMonte Rosa   0.13   
1.0%
0%
DSGNDesign Therapeutics   0.64   
6.0%
0%
APLSApellis Pharmaceuticals   1.48   
15.0%
0%
TVTXTravere Therapeutics   1.63   
16.0%
0%
BGNEBeiGene   1.78   
18.0%
0%
LEGNLegend Biotech   2.05   
21.0%
0%
BDTXBlack Diamond   2.56   
26.0%
0%
STOKStoke Therapeutics   3.24   
33.0%
0%
ASNDAscendis Pharma   3.28   
33.0%
0%
IKNAIkena Oncology   4.32   
44.0%
0%
SWTXSpringWorks Therapeutics   4.56   
46.0%
0%
PCVXVaxcyte   4.57   
46.0%
0%
FDMT4D Molecular   5.54   
56.0%
0%
AKROAkero Therapeutics   6.21   
63.0%
0%
RNAAvidity Biosciences   6.23   
63.0%
0%
HOWLWerewolf Therapeutics   9.76   
100.0%
0%

Complementary Tools for Denali Stock analysis

When running Denali Therapeutics' price analysis, check to measure Denali Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Denali Therapeutics is operating at the current time. Most of Denali Therapeutics' value examination focuses on studying past and present price action to predict the probability of Denali Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Denali Therapeutics' price. Additionally, you may evaluate how the addition of Denali Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Transaction History
View history of all your transactions and understand their impact on performance
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years